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The presence of polyvascular disease, defined as atherosclerosis involving >1 distinct vascular territory, is a strong, independent predictor of cardiovascu-lar events.1–4 In the LEADER trial (Liraglutide Effect and Action in Diabetes: 
Evaluation of Cardiovascular Outcome Results),5 the human glucagon-like peptide 
1 analog liraglutide reduced cardiovascular events in patients with type 2 diabetes 
mellitus at high cardiovascular risk. In this post hoc analysis of LEADER, we evalu-
ated the effects of liraglutide stratified by a number of atherosclerotic vascular 
territories (coronary, cerebrovascular, and peripheral).
LEADER (ClinicalTrials.gov, NCT01179048) was a randomized trial of liraglutide 
(1.8 mg or maximum tolerated dose) versus placebo in 9340 patients with type 2 
diabetes mellitus and high cardiovascular risk (median follow-up, 3.8 years).5 The 
primary outcome was a composite of cardiovascular death, nonfatal myocardial 
infarction, or nonfatal stroke (major adverse cardiovascular events [MACE]). The 
key secondary expanded outcome (expanded MACE) also included hospitalization 
for unstable angina, coronary revascularization, or hospitalization for heart failure.
The ethics committee or institutional review board at each participating center 
approved the trial protocol. Patients provided informed consent. Cardiovascular 
outcomes were prospectively adjudicated by an independent, blinded event ad-
judication committee. Atherosclerotic vascular territories included coronary (myo-
cardial infarction, ≥50% coronary artery stenosis, percutaneous coronary inter-
vention or coronary artery bypass graft surgery, angina pectoris, or asymptomatic 
ischemia), cerebrovascular (stroke, transient ischemic attack, ≥50% intracranial 
or carotid artery stenosis), and peripheral (≥50% peripheral artery stenosis) arter-
ies. Information was extracted from patients’ baseline medical history. Risk groups 
were determined by number of vascular territories involved: polyvascular disease as 
≥2, single vascular disease as 1, and a group with no documented atherosclerotic 
cardiovascular disease (ASCVD).
The hazard ratios (HRs) comparing risk groups were calculated using a Cox pro-
portional hazards model with treatment and risk group as factors. The treatment 
effect of liraglutide versus placebo within risk groups was estimated by using the 
Cox proportional hazards regression model with treatment, risk group, and the 
interaction of both as factors.
In LEADER, 6775 patients (72.5%) had documented ASCVD. In patients with 
ASCVD, 1536 (23%) had a baseline history of polyvascular disease, and 5239 
(77%) had single vascular disease. For the total population, the distribution of 
vascular territory involvement is shown in the Figure (A). In brief, 5364 patients 
(57.4%) had a history of coronary artery disease, 1968 (21.1%) had cerebrovas-
cular disease, 1184 (12.7%) had peripheral artery disease, and 2565 (27.5%) had 
no documented ASCVD. At baseline, in patients with polyvascular disease versus 
single vascular disease, mean age±SD was higher (65.1±7.7 versus 63.5±7.3 
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years), and more patients were male (68.8% versus 
67.9%), were current or previous smokers (67.1% 
versus 60.1%), had an estimated glomerular filtration 
rate <60 mL·min–1·1.73m–2 (27.1% versus 19.0%), 
had history of heart failure (26.4% versus 16.5%), 
had history of myocardial infarction (47.2% versus 
39.7%), had history of stroke (33.5% versus 10.0%), 
or had history of peripheral artery disease (47.1% 
versus 8.5%), and there was a higher frequency of 
cardiovascular medication use (95.6% versus 92.7% 
for antihypertensive therapy, 83.8% versus 79.2% 
for lipid-lowering therapy, and 79.7% versus 75.7% 
for antiplatelet therapy). Baseline hemoglobin A1c was 
similar between groups.
Patients with polyvascular disease had a higher risk 
of cardiovascular outcomes than those with single vas-
cular disease (MACE: HR, 1.52; 95% confidence inter-
val [CI], 1.33–1.73; expanded MACE: HR, 1.45; 95% 
CI, 1.31–1.62; cardiovascular death: HR, 1.41; 95% CI, 
1.13–1.75) (Figure [B and C]).
A
B
Figure. Analysis of LEADER data stratified by the number of atherosclerotic vascular territories (no ASCVD: no 
documented evidence of atherosclerotic disease in any of 3 vascular territories [coronary artery, cerebrovascular, 
or peripheral artery]; single vascular disease: atherosclerotic disease in 1 of the 3 vascular territories; polyvascular 
disease: atherosclerotic disease in ≥2 of the specified vascular territories).  
A, Venn diagram of number (%) of patients according to number of vascular territories involved at baseline. B, Kaplan-Meier 
estimates (based on number of vascular territories involved at baseline) of time to first: primary MACE (composite of cardio-
vascular death, nonfatal myocardial infarction, or nonfatal stroke) (i), and expanded MACE (composite of the primary, with 
hospitalization for unstable angina, coronary revascularization, or hospitalization for heart failure also included) (ii). C, Cardio-
vascular outcomes by number of vascular territories involved. Hazard ratios and 95% CIs are based on Cox regression analyses. 
Interaction P value is for test of homogeneity of treatment group difference among all 3 subgroups (no ASCVD, single vascular 
disease, and, polyvascular disease) with no adjustment for multiple tests. ASCVD indicates atherosclerotic cardiovascular dis-
ease; CAD, coronary artery disease; CD, cerebrovascular disease; CI, confidence interval; LEADER, Liraglutide Effect and Action 
in Diabetes: Evaluation of Cardiovascular Outcome Results; MACE, major adverse cardiovascular event; and PAD, peripheral 
artery disease.
quire a longer treatment period or larger sample size. 
Nevertheless, patients with type 2 diabetes mellitus 
benefit from liraglutide treatment regarding glycemic 
control, potential weight reductions, and better blood 
pressure control.5
In patients with type 2 diabetes mellitus and docu-
mented ASCVD, the presence of polyvascular disease 
was associated with greater cardiovascular risk versus 
those with single vascular disease. Liraglutide consis-
tently appeared to reduce major cardiovascular out-
comes in both patients with polyvascular and single 
vascular disease.
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Liraglutide reduced MACE consistently in patients 
with polyvascular disease (HR, 0.82; 95% CI, 0.66–
1.02) and with single vascular disease (HR, 0.82; 95% 
CI, 0.71–0.95). Results were similar for expanded MACE 
and cardiovascular death (Figure [C]). The risk reduction 
in MACE and expanded MACE was similar to that of 
the total trial population in LEADER (Figure [C]).5 The 
corresponding data for nonfatal myocardial infarction 
and stroke are displayed in the Figure (C).
In patients without ASCVD at baseline, the HR for 
liraglutide versus placebo for MACE was 1.08 (95% 
CI, 0.84–1.38), with similar results for expanded 
MACE and cardiovascular death (Figure [C]). How-
ever, no significant interaction was found among risk 
groups, with the exception of expanded MACE (Pinterac-
=0.03), which could be a chance finding, because 
tion
no adjustment for multiple testing was performed, or 
may suggest a difference in treatment effects across 
risk groups, driven by the group without ASCVD (Fig-
ure [C]). The reason for a neutral response in patients 
without ASCVD could be that the baseline risk was 
lower, and to establish any potential effect might re-
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